Claris Lifesciences Inc. is recalling Ciprofloxacin in Dextrose (5%) Injection, USP 200 mg in 100 mL, a prescription antibiotic used to treat various bacterial infections. This recall was initiated because the product was found to be superpotent, meaning it contains a higher concentration of the active drug than intended. Consumers should be aware that this affects 100 mL flexible bags manufactured for Claris Lifesciences Inc. and distributed nationwide.
Superpotent medication delivers a higher dose of the drug than prescribed, which can increase the risk of serious side effects or adverse reactions. Patients receiving this superpotent antibiotic may experience toxicity or other complications related to an overdose of ciprofloxacin.
Refund for superpotent drug
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.